参考文献
［1］Torre L A，Bray F，Siegel R L，et al.Global cancer statistics，2012［J］.CA Cancer J Clin，2015，65（2）：87-108.
［2］Chen W，Zheng R，Baade P D，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66（2）：115-132.
［3］Kim J M，Kwon C H，Joh J W，et al.Incidental microscopic bile duct tumor thrombi in hepatocellular carcinoma after curative hepatectomy：a matched study［J］.Medicine（Baltimore），2015，94（6）：e450.
［4］Kim D S，Kim B W，Hatano E，et al.Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus：a Korea-Japan multicenter study［J］.Ann Surg，2020，271（5）：913-921.
［5］Luo X J，Tan W F，Yi B，et al.Surgery of hepatocellular carcinoma complicated with cancer thrombi in bile duct：efficacy for criteria for different therapy modalities［J］.Langenbecks Arch Surg，2009，394（6）：1033-1039.
［6］Choi J，Shim J H，Park D H，et al.Clinical usefulness of endoscopic palliation in patients with biliary obstruction caused by hepatocellular carcinoma［J］.Digestion，2013，88（2）：87-94.
［7］Suh Y G，Kim D Y，Han K H，et al.Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice［J］.Gut Liver，2014，8（5）：526-535.
［8］Qin L X，Tang Z Y.Hepatocellular carcinoma with obstructive jaundice：diagnosis，treatment and prognosis［J］.World J Gastroenterol，2003，9（3）：385-391.
［9］Ryder S D，British Society of Gastroenterology.Guidelines for the diagnosis and treatment of hepatocellular carcinoma（HCC）in adults［J］.Gut，2003，52（suppl 3）：1-8.
［10］U.S.Preventive Services Task Force.Grade Definitions and Suggestions for Practice.2012；Available from：http://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions.
［11］Liu Q Y，Huang S Q，Chen J Y，et al.Small hepatocellular carcinoma with bile duct tumor thrombi：CT and MRI findings［J］.Abdom Imaging，2010，35（5）：537-542.
［12］Zhang W，Fang C，Liu H，et al.FDG PET/CT imaging of hepatocellular carcinoma with bile duct tumor thrombus［J］.Clin Nucl Med，2019，44（2）：130-132.
［13］Lu Z，Sun W，Wen F，et al.Clinical application of percutaneous drainage in treating hepatocellular carcinoma with bile duct tumor thrombus［J］.Contemp Oncol（Pozn），2013，17（2）：176-183.
［14］Koh Y X，Lee S Y，Chok A Y，et al.Icteric Intraductal hepatocellular carcinoma and bile duct thrombus masquerading as hilar cholangiocarcinoma［J］.Ann Acad Med Singap，2016，45（3）：113-116.
［15］Zhou X，Wang J，Tang M，et al.Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar cholangiocarcinoma on enhanced computed tomography：a diagnostic challenge［J］.BMC Cancer，2020，20（1）：54.
［16］Ueda M，Takeuchi T，Takayasu T，et al.Classification and surgical treatment of hepatocellular carcinoma（HCC）with bile duct thrombi［J］.Hepatogastroenterology，1994，41（4）：349-354.
［17］Satoh S，Ikai I，Honda G，et al.Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi［J］.Surgery，2000，128（5）：779-783.
［18］Liver Cancer Study Group of Japan.General rules for the clinical and pathological study of primary liver cancer［M］.3rd ed.Tokyo：Kanehara & Co.Ltd，2010.
［19］Sun J X，Wu J Y，Liu C，et al.Typing of biliary tumor thrombus influences prognosis of patients with hepatocellular carcinoma［J］.Cancer Biol Med，2021，18（3）：808-815.
［20］Moon D B，Hwang S，Wang H J，et al.Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus：a Korean Multicenter study［J］.World J Surg，2013，37（2）：443-451.
［21］Wang D D，Wu L Q，Wang Z S.Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection：a matched study［J］.Hepatobiliary Pancreat Dis Int，2016，15（6）：626-632.
［22］Esaki M，Shimada K，Sano T，et al.Surgical results for hepatocellular carcinoma with bile duct invasion：A clinicopathologic comparison between macroscopic and microscopic tumor thrombus［J］.J Surg Oncol，2005，90（4）：226-232.
［23］Kasai Y，Hatano E，Seo S，et al.Hepatocellular carcinoma with bile duct tumor thrombus：surgical outcomes and the prognostic impact of concomitant major vascular invasion［J］.World J Surg，2015，39（6）：1485-1493.
［24］Wong T C L，Cheung T T，Chok K S H，et al.Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus［J］.HPB，2014，17（5）：401-408.
［25］Hu X G，Mao W，Hong S Y，et al.Surgical treatment for hepatocellular carcinoma with bile duct invasion［J］.Ann Surg Treat Res，2016，90（3）：139-146.
［26］Navadgi S，Chang C C，Bartlett A，et al.Systematic review and meta-analysis of outcomes after liver resection in patients with hepatocellular carcinoma（HCC）with and without bile duct thrombus［J］.HPB（Oxford），2016，18（4）：312-316.(https://www.daowen.com)
［27］Wu J Y，Sun J X，Lau W Y，et al.Surgical resection for hepatocellular carcinoma with bile duct tumor thrombus［J］.Surgery，2021，S0039-6060（21）0010-6.
［28］Sun J，Wu J，Shi J，et al.Thrombus-First Surgery for hepatocellular carcinoma with bile duct tumor thrombus［J］.J Gastrointest Surg，2021，25（8）：1973-1979.
［29］Kim J M，Kwon C H D，Joh J W，et al.The effect of hepatocellular carcinoma bile duct tumor thrombi in liver transplantation［J］.Hepatogastroenterology，2014，61（134）：1673-1676.
［30］Yu X H，Xu L B，Liu C，et al.Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi［J］.Dig Dis Sci，2011，56（1）：252-259.
［31］Shen Y，Li P，Cui K，et al.Neoadjuvant transcatheter artetial chemoembolization for biliary tumor thrombpsis：a retrospective study［J］.Int J Technol Assess Health Care，2016，32（4）：212-217.
［32］Fukuda S，Okuda K，Imamura M，et al.Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus：report of 19 cases［J］.Surgery，2002，131（3）：300-310.
［33］Ha T Y，Hwang S，Moon D B，et al.Long-term survival analysis of liver transplantation for hepatocellular carcinoma with bile duct tumor thrombus［J］.Transplant Proc，2014，46（3）：774-777.
［34］Cui W，Xu R，Wang Y，et al.Percutaneous endobiliary radiofrequency ablation and stents in management of hepatocellular carcinoma with bile duct tumor thrombus：Initial single-institu tion experience［J］.Asia Pac JClin Oncol，2020，16（4）：259-265.
［35］Minami Y，Kudo M.Hepatocellular carcinoma with obstructive jaundice：endoscopic and percutaneous biliary drainage［J］.Dig Dis，2012，30（6）：592-597.
［36］Choi J，Ryu J K，Lee S H，et al.Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization［J］.J Palliat Med，2013，16（9）：1026-1033.
［37］Braden B，Gupta V，Dietrich C F.Therapeutic EUS：New tools，new devices，new applications［J］.Endosc Ultrasound，2019，8（6）：370-381.
［38］Li S，He X，Dang L，et al.Efficacy of 125I versus Non-125I combined with transcatheter arterialchemoembolization for the treatment of unresectable hepatocellular carcinoma with obstructive jaundice［J］.Dig Dis Sci，2018，63（2）：321-328.
［39］Iwamoto H，Nomiyama M，Niizeki T，et al.Dose and location of irradiation determine survival for patients with hepatocellular carcinoma with macrovascular invasion in external beam radiation therapy［J］.Oncology，2019，96（4）：192-199.
［40］Huang J F，Wang L Y，Lin Z Y，et al.Incidence and clinical outcome of icteric type hepatocellular carcinoma［J］.J Gastroenterol Hepatol，2002，17（2）：190-195.
［41］Xu X，Li J，Wu J，et al.A Systematic review and meta-analysis of intraluminal brachytherapy versus stent alone in the treatment of malignant obstructive jaundice［J］.Cardiovasc Intervent Radiol，2018，41（2）：206-217.
［42］肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识［J］.肿瘤，2014，34（4）：295-302.
［43］Lee M S，Ryoo B Y，Hsu C H，et al.GO30140 investigators.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma（GO30140）：an openlabel，multicentre，phase lb study［J］.Lancet Oncol，2020，21（6）：808-820.
［44］Bruix J，Raoul J L，Sherman M，et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma：subanalyses of a phase Ⅲ trial［J］.J Hepatol，2012，57（4）：821-829.
［45］Kudo M，Finn R S，Qin S，et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma：a randomised phase 3 noninferiority trial［J］.Lancet，2018，391（10126）：1163-1173.
［46］Bruix J，Qin S，Merle P，et al.Resorce investigators.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment（RESORCE）：a randomised，double-blind，placebo-controlled，phase 3 trial［J］.Lancet，2017，389（10064）：56-66.
［47］Qin S，Bai Y，Lim H Y，et al.Randomized，multicenter，openlabel study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with ad vanced hepatocellular carcinoma from Asia［J］.J Clin Oncol，2013，31（28）：3501-3508.
［48］Finn R S，Qin S，Ikeda M，et al.IMbrave 150 investigators.atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］.N Engl J Med，2020，382（20）：1894-1905.
［49］中国医师协会肝癌专业委员会.肝细胞癌合并门静脉癌栓多学科诊治中国专家共识（2018年版）［J］.中国实用外科杂志，2019，39（1）：46-52.
［50］中国医师协会肝癌专业委员会.肝细胞癌合并肝静脉或下腔静脉癌栓多学科诊治中国专家共识（2019版）［J］.中国实用外科杂志，2020，40（1）：17-22.
［51］中华医学会外科学分会脾及门静脉高压外科学组.肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识（2019版）［J］.中国实用外科杂志，2019，39（12）：1241-1247.
（本文引自《中国实用外科杂志》2021年第41卷第3期）